PDS Biotech’s Q2 2024 Update: Clinical Progress
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
- Latest
- Trending
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
Published results show a 36-month survival rate of 20% with immunotherapy. ICI resistant group had a 72% 12-month OS rate. ...
Clinical-stage biotech company Coya Therapeutics expands its IP portfolio with a license for a novel combination therapy using low dose ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.